JPMorgan Upgrades Biogen Ahead of Key Data Readouts
JPMorgan raised Biogen to overweight from neutral ahead of data on felzartamab and litifilimab. Shares gained 3.6% premarket.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Biogen is moving toward a more promising outlook, according to JPMorgan analysts. In a note cited by Dow Jones Newswires, they said the company is nearing several important data readouts scheduled for next year.
The expected updates include felzartamab, a potential treatment for antibody-mediated rejection. The analysts estimate that the drug could represent an opportunity worth more than $2 billion. They also expect data on Biogen’s litifilimab in cutaneous lupus erythematosus.
JPMorgan lifted its rating on the stock to overweight from neutral. The analysts described BIIB as one of the more attractive names heading into 2027 as Biogen develops beyond a story focused solely on Leqembi. Biogen shares were up 3.6% premarket.
why it matters
The upgrade highlights JPMorgan’s view that Biogen’s longer-term profile may depend on several pipeline assets rather than Leqembi alone. Upcoming data for felzartamab and litifilimab could therefore remain important market catalysts for BIIB.
instruments
sources
- Biogen Gets JPMorgan Upgrade Ahead of Key Data Readouts — Market Talk — Dow Jones Newswires, 12 October 2026 at 12:34 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗